Unafraid to Ask More: The Artificial Pancreas

Unafraid to Ask More: Artificial Pancreas

Type 1 diabetes affects more than 2.5 million Americans. This UVA startup is building an artificial pancreas to help them.

Posted by University of Virginia on Thursday, October 26, 2017

Joshua Davis’ Experience using the Artificial Pancreas

Check out this video of 7 year old Joshua Davis as he describes his experiences and glycemic control while using the InControl Artificial Pancreas technology during the Center for Diabetes Technology’s recent AP Use in Young Children study . If you are interested in the overall results of the AP Use in Young Children Study, click here.

JDRF Children’s Congress

Joshua is a soccer player and his dad—who also has T1D—is his coach. He was excited to take part in the University of Virginia artificial pancreas project, a three-day camp where he was able to be very active without worrying about his blood sugar.

Source: Joshua – JDRF Children’s Congress

Final artificial pancreas clinical trials now open

Clinical trials are now enrolling to provide the final tests for a University of Virginia-developed artificial pancreas to automatically monitor and regulate blood-sugar levels in people with type 1 diabetes.

If you or a loved one would like to participate in Charlottesville, please click on the participate tab. Otherwise, you can visit the International Diabetes Closed-Loop website to contact one of the 9 other clinical trial centers.

Click here to read the article on UVA Health

Strategic Investment Fund to Advance Diabetes Research

New approvals from the Board of Visitors Strategic Investment Fund will provide resources supporting the ongoing fight to end childhood diabetes…

Visit UVA Today to find out more.


Power of the Artificial Pancreas

An artificial pancreas device could give patients with diabetes a way to manage the disease while affording them more freedom in everyday life.

CDT Director Boris Kovatchev was recently featured in UVAToday’s article, the Power of the Artificial Pancreas.


6-year-old participates in trial

The CDT just completed its first artificial pancreas study for children ages 5 to 8 years old. Read more about this wonderful experience on The Tidewater News.



Follow as one of our trial participants blogs about his experience on the DiAs!

Continuous use of closed-loop system increases time in range, decreases hypoglycemia

Results from one of the CDT’s recent studies showed that by using closed-loop control 24/7

median time at less than 70 mg/dL decreased from 4.1% at baseline to 1.7% (P < .001), median time in target increased from 65% to 73% (P < .001), median time at more than 180 mg/dL decreased from 32% to 25% (P = .001) and median coefficient of variation decreased from 38% to 34% (P < .001).


Marc Breton Describes Artificial Pancreas Components – YouTube

In the video below, UVA engineer Marc Breton describes the current state of the CDT’s artificial pancreas algorithms!